Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Nanjing Healthnice Pharmaceutical Technology has commercial products approved in China (e.g., avatrombopag for thrombocytopenia), and ongoing clinical development programs for metabolic, fibrotic, and respiratory diseases. Their drugs target liver fibrosis (hydronidone), pulmonary arterial hypertension, COPD, diabetes, and gastric reflux, with several in mid- to late-stage clinical trials and some in preclinical stages. Topline results from recent Phase 3 liver fibrosis trials are pending.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Nanjing Healthnice Pharmaceutical Technology.